Ingilterra - Ingliż - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - buprenorphine - transdermal patch - 70microgram/1hour

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - nicotine, quantity: 114 mg (equivalent: nicotine, qty 21 mg/24 h) - drug delivery system, transdermal - excipient ingredients: polyethylene; ethylene dioleamide; ethylene/vinyl acetate copolymer; polyisobutylene; titanium dioxide; ethyl acetate; ethanol; isopropyl alcohol; methoxyisopropanol; ethylcellulose; pyroxylin - for the treatment of nicotine dependence as an aid to smoking cessation.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - nicotine, quantity: 78 mg (equivalent: nicotine, qty 14 mg/24 h) - drug delivery system, transdermal - excipient ingredients: ethylene dioleamide; polyethylene; ethylene/vinyl acetate copolymer; polyisobutylene; titanium dioxide; ethyl acetate; ethanol; isopropyl alcohol; methoxyisopropanol; ethylcellulose; pyroxylin - for the treatment of nicotine dependence as an aid to smoking cessation.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

haleon australia pty ltd - nicotine, quantity: 36 mg (equivalent: nicotine, qty 7 mg/24 h) - drug delivery system, transdermal - excipient ingredients: ethylene dioleamide; polyisobutylene; ethylene/vinyl acetate copolymer; polyethylene; titanium dioxide; ethyl acetate; ethanol; isopropyl alcohol; methoxyisopropanol; ethylcellulose; pyroxylin - for the treatment of nicotine dependence as an aid to smoking cessation.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - estradiol hemihydrate, quantity: 2.32 mg (equivalent: estradiol, qty 2.25 mg) - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; isopropyl palmitate; ethyl acetate; acrylic acid; 2-ethylhexyl acrylate; methyl acrylate; glycidyl methacrylate; 2,2'-azobisisobutyronitrile; hexane - menopausal symptoms: short-term treatment of signs and symptoms of oestrogen deficiency due to menopause, whether natural or surgically induced. in women with an intact uterus, oestrogen should always be opposed by progestogen in an adequate dosage regimen to ensure secretory transformation of the endometrium at regular intervals (refer to section 5.1 pharmacodynamic properties - clinical trials and section 4.2 dose and method of administration). prevention of post-menopausal bone mineral density loss: estraderm mx 50, 75 and 100 may be used for prevention of post-menopausal bone mineral density loss in women with an increased risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. when prescribed solely for the prevention of postmenopausal bone mineral density loss, therapy should only be prescribed for women who are at high risk of future fracture and who are intolerant of, or contraindicated for, non-oestrogen products approved for prevention of bone mineral density loss. lifestyle modifications and the risk-benefit profile of estraderm mx should be taken into careful consideration and discussed with the patient to allow the patient to make an informed decision prior to prescribing (see section 4.4 special warnings and precautions for use and section 4.2 dose and method of administration). combination hrt should not be used in hysterectomised women because it is not needed in these women and it may increase risk of breast cancer.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

symbiotic devices pty ltd - 47714 - subdermal needle electrode - a sterile electrical conductor inserted beneath the dermal layer of a patient's skin to record/monitor electrical activity (biopotentials) for a range of physiological measurements and also to provide electrical stimulation usually for intraoperative monitoring and/or nerve location.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

kh nxgen aus pty ltd - 47714 - subdermal needle electrode - disposable subdermal needle electrodes are placed subcutaneously to stimulate or record electrical signals with the electroneurodiagnostic or other emg monitors.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

browology pty ltd - 37474 - transdermal needle roller, reusable - derma roller is a topical epidermal device used for cell rejuvenation, improvement in complexion, reduces fine line and wrinkles and provides absorption of nutrients. composition 9 disks x 60 needles (540 needles for face) needle material fine titanium handle / roller material pc+abs packaging high sealing sterilization packaging how to clean the derma roller -soak about 5~8 minutes with 75% alcohol, or use ultraviolet to disinfect for 45mins -please store it carefully,it should be placed out of reach of children! -all dermaroller are disposable and personal use,do not share with other people. used method 1. clean your face in common way. clean the dermaroller. 2. after about 15minutes, put micro-needles end on your face and make it roll on your face. 3. do not use it in heavy press into your skin,in mild pressure! 4. clean the derma roller after use. store it in dry & clean place. it is advised to be single use if disinfection/sterlization has not been complied. however, it is recommended to clean with 75%

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

au pharma pty ltd - buprenorphine, quantity: 15 mg - drug delivery system, transdermal - excipient ingredients: povidone; levulinic acid; oleyl oleate; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - b-patch patches are indicated for the management of severe pain where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - requires daily, continuous, long-term treatment,b-patch patches are not indicated for use in chronic non-cancer pain other than in exception circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

au pharma pty ltd - buprenorphine, quantity: 5 mg - drug delivery system, transdermal - excipient ingredients: povidone; oleyl oleate; polyethylene terephthalate; levulinic acid; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; butyl acrylate; acrylic acid; 2,2'-azobisisobutyronitrile; aluminium acetylacetonate; heptane; glycidyl methacrylate; 2-hydroxyethyl acrylate - b-patch patches are indicated for the management of severe pain where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment.,b-patch patches are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. b-patch patches are not indicated as an as-needed (prn) analgesia.